Developer docs
API playgroundTry for free, no card

Search company profiles

Epithelix

Full company profile

uuid000i79y

Namestring
Epithelix
Legal namestring
Epithelix Sàrl
Websiteurl
epithelix.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Epithelix Sàrl, founded in March 2006 in Plan-les-Ouates (Geneva, Switzerland) by three University of Geneva scientists — Dr. Samuel Constant, Dr. Song Huang and Dr. Ludovic Wiszniewski — develops and commercializes in vitro 3D reconstituted human respiratory epithelium tissues cultured at the air-liquid interface (ALI) as alternatives to animal experimentation. The company's core platform consists of three primary tissue models: MucilAir™ (upper respiratory tract, available in nasal, tracheal and bronchial variants), SmallAir™ (lower respiratory tract / bronchiolar region) and AlveolAir™ (alveolar epithelium), each maintained in a proprietary differentiated and functional state for more than one year — a performance capability the company positions as unique versus other respiratory models. The product range is broadened by advanced co-culture versions (with primary human fibroblasts or alveolar macrophages), pathological-tissue variants (Smoker, Allergic Rhinitis, Asthma, COPD, Cystic Fibrosis), cryopreserved primary cells (hAEC, hSAEC, fibroblasts, pneumocytes, alveolar macrophages) and a suite of serum-free, chemically defined culture media.

Revenue is generated through two complementary streams: (1) catalog product sales of tissues, cryopreserved cells, media and companion reagents on a one-time-purchase basis, and (2) contract research (CRO) services covering viral and bacterial infection assays, nasal spray evaluation, inhalation toxicity, anti-inflammatory and cystic fibrosis efficacy testing, absorption/permeation, metaplasia, mucolytic activity, nasal dryness, wound healing, electrophysiology, and mucociliary clearance analysis, supported by exposure systems (Vitrocell Cloud, Vitrocell VC1, NanoPress) and the proprietary Cilia-X CBF analysis software. Pricing is quote-based via direct email requests, with free test samples offered to new accounts. The go-to-market combines direct sales from Swiss and French facilities with regional channel partners in the US (Institute of In Vitro Sciences), Japan (Iwaki & Co., since January 2010), South Korea (BN Korea) and India (Krishgen BioSystems); customer segments span pharmaceutical, chemical/consumer products (including cosmetics and inhalation product testing), academic research, government/regulatory bodies, and medical-device developers, with named users including Johns Hopkins School of Medicine, Public Health England, the Slovak Academy of Sciences and the University of Freiburg. The company is self-financed (no disclosed external equity), maintains a wholly-owned French subsidiary and a wholly-owned cancer-research spin-off (OncoTheis), and reports a headcount of 20+ full-time staff across both sites.

Short descriptiontext

Epithelix Sàrl develops and commercializes proprietary in vitro 3D reconstituted human respiratory epithelium tissues (MucilAir™, SmallAir™, AlveolAir™) and related contract research services, serving pharmaceutical, chemical, cosmetics, medical-device, academic and government customers seeking alternatives to animal respiratory testing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPlan-les-ouates, Switzerland
HQ citystring
Plan-les-ouates
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vitro respiratory tissues, 3D airway epithelium models, preclinical inhalation toxicology, alternatives to animal testing, human respiratory tissue models
Industry3 codes
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKANAD
Asthma & Allergy-Related Pulmonary Care
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
In Vitro Respiratory Tissue Models
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Tissue and Cell Products
TypeOne Time License
Description

Sale of in vitro reconstituted human respiratory tissues (MucilAir, SmallAir, AlveolAir) and cryopreserved primary cells (hAEC, hSAEC, fibroblasts, alveolar pneumocytes, alveolar macrophages) along with specialized culture media.

epithelix.com
2Contract Research Services (CRO)
TypeProfessional Services
Description

In vitro testing services including viral infections, bacterial infections, nasal spray evaluation, inhalation toxicity, anti-inflammatory, cystic fibrosis, absorption-permeation, metaplasia, mucolytic activity, nasal dryness, wound healing assays, electrophysiology, and mucociliary clearance analysis.

epithelix.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1MucilAir™
Description

In vitro 3D human respiratory epithelium model from nasal, tracheal, or bronchial origin. The only human respiratory epithelium model able to remain fully differentiated and functional for more than one year.

epithelix.com
+6 more records
Core offering1 text field

Epithelix develops and sells in vitro 3D reconstituted human respiratory epithelium tissues (MucilAir™, SmallAir™, AlveolAir™) cultured at air-liquid interface, along with co-culture models, cryopreserved primary airway cells, tissue-specific serum-free culture media, the proprietary Cilia-X analysis software, and a suite of contract research testing services for respiratory drug development, inhalation toxicology, infectious disease research, and disease modeling.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Tissues can remain fully differentiated and functional for more than one year
+3 more records
Product overview1 text field

Epithelix provides a comprehensive portfolio of in vitro respiratory solutions centered on reconstituted human 3D airway tissues and associated testing services. The core product line includes three primary 3D tissue models: MucilAir™ (upper respiratory epithelium available in nasal, tracheal, and bronchial versions), SmallAir™ (lower bronchiolar epithelium), and AlveolAir™ (alveolar epithelium). These are complemented by advanced co-culture models incorporating fibroblasts or macrophages, and an extensive catalog of cryopreserved primary cells (hAEC, hSAEC, pneumocytes, alveolar macrophages, fibroblasts). Supporting the tissue products are purpose-designed serum-free culture media for each tissue type. As a CRO, Epithelix offers extensive testing services including viral/bacterial infection assays, inhalation toxicity, drug absorption studies, anti-inflammatory evaluation, and specialized endpoints such as electrophysiology and mucociliary clearance analysis. The company also provides proprietary analysis software (Cilia-X) and exposure devices for aerosol testing.

Product and service15 records
1MucilAir™
CategoryIn vitro tissue model
Description

In vitro 3D reconstituted human upper respiratory epithelium comprising basal, goblet, and ciliated cells, available in nasal, tracheal, and bronchial regions, for pharmaceutical, chemical, cosmetics, and academic respiratory research.

2SmallAir™
CategoryIn vitro tissue model
Description

In vitro 3D reconstituted human bronchiolar epithelium model targeting the small airways for research on asthma, COPD, and bronchiolar disease.

3AlveolAir™
CategoryIn vitro tissue model
Description

In vitro 3D reconstituted human alveolar epithelium model for studying deep-lung biology, drug delivery, and alveolar pathology.

4MA / SA -HF Advanced Co-culture Models
CategoryAdvanced co-culture tissue model
Description

MucilAir or SmallAir tissue co-cultured with primary human pulmonary fibroblasts for studies requiring stromal-epithelial interactions.

5MA / SA / AA -Macrophages Co-culture Models
CategoryAdvanced co-culture tissue model
Description

Epithelial tissues combined with primary human alveolar macrophages for modelling innate immune and inflammatory responses in the respiratory tract.

6hAEC Upper Airway Epithelial Cells
CategoryCryopreserved primary cells
Description

Cryopreserved low-passage primary human upper airway epithelial cells supplied for 2D or ALI culture use in respiratory research.

7hSAEC Small Airway Epithelial Cells
CategoryCryopreserved primary cells
Description

Cryopreserved low-passage primary human small airway epithelial cells for use in disease modeling and toxicology research.

8Pulmonary Fibroblasts (HF)
CategoryCryopreserved primary cells
Description

Cryopreserved low-passage primary human pulmonary fibroblasts for co-culture and stromal interaction studies.

9Alveolar Pneumocytes
CategoryCryopreserved primary cells
Description

Cryopreserved low-passage primary human alveolar pneumocytes (Type I and Type II) for alveolar biology and inhalation studies.

10Alveolar Macrophages
CategoryCryopreserved primary cells
Description

Cryopreserved primary human resident alveolar macrophages (more than 1 million viable cells per vial) for co-culture, innate immunity, and infection studies.

11Cells and Tissues Extracts
CategoryCell and tissue extract products
Description

Prepared extracts (mucus, total RNA, protein lysate) from MucilAir tissues for downstream biochemical and omics analyses.

12Tissue-specific Serum-free Culture Media (MucilAir / SmallAir / AlveolAir / hAEC-hSAEC / Macrophage / Pneumocyte)
CategoryCulture media
Description

Serum-free chemically defined culture media tailored to each Epithelix tissue and primary cell type, available in formats such as 125 mL and 500 mL bottles.

13Cilia-X CBF Analysis Software
CategoryAnalysis software
Description

Proprietary cross-platform web application for batch cilia beating frequency analysis, supporting image series, video files, and Nikon ND2 files with automated reporting.

14In Vitro Contract Research Testing Services (CRO)
CategoryContract research organization (CRO) services
Description

Fee-for-service in vitro testing on Epithelix airway tissues including viral and bacterial infection assays, inhalation toxicity, anti-inflammatory studies, cystic fibrosis assays, absorption/permeation, metaplasia, mucolytic activity, nasal dryness, wound healing, electrophysiology, mucociliary clearance, and endpoint measurements for pharmaceutical, chemical, cosmetics, and academic clients.

15Inhalation Exposure Devices
CategoryExposure and testing equipment
Description

Static and dynamic exposure devices including NanoPress (solid tablets), Vitrocell Cloud (nebulized liquids), and Vitrocell VC1 (gas or smoke) for testing airborne substances on Epithelix tissues, supplied and integrated for client studies.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeTechnology or Integration
Description

Vitrocell Systems offers culture and exposure systems for in vitro studies on gases or complex mixtures. The VITROCELL modules adapted to MucilAir and SmallAir provide new possibilities for characterizing effects of airborne substances such as gas, nanoparticles, and complex mixtures.

2Panviprep
Strategic tierMajorTypeStrategic or Co-development Partner
Description

The PANVIPREP consortium incorporates 14 European partners working to contribute to antiviral pandemic preparedness by piloting and progressing antiviral drug development targeting RNA virus families with high epidemic or pandemic potential.

epithelix.com
3Nosevac
Strategic tierMajorTypeStrategic or Co-development Partner
Description

NOSEVAC consortium aims to cultivate and evaluate inventive nasal vaccine platforms to prevent earliest stage of infection and inhibit upper respiratory tract colonisation and transmission. Funding from EU, UK, and Swiss governments.

epithelix.com
4MACRAMÉ
Strategic tierMajorTypeStrategic or Co-development Partner
Description

MACRAMÉ Project aligned with EU ambitions for safety and sustainability of chemicals, focusing on nanomaterials and Advanced Materials. Development of novel methodologies for inhalable carbon-based materials including graphene-related materials and carbon nanotubes.

epithelix.com
5FAIR
Strategic tierCoreTypeStrategic or Co-development Partner
Description

FAIR is an EU Horizon 2020 project that aims at evaluating the activation of the innate immune system in the airways. Provides an alternative adjunct strategy to standard of care antibiotics for treating pneumonia caused by antibiotic-resistant bacteria.

epithelix.com
6Organovir
Strategic tierCoreTypeStrategic or Co-development Partner
Description

OrganoVIR is a Horizon 2020 Marie Sklowdowska-Curie Actions Innovative Training Network (MSCA-ITN) that trains 15 Early Stage Researchers to lead innovation in organoids for virology. Epithelix is a partner in the consortium.

epithelix.com
7Onconanoscreen
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Onconanoscreen is an Interreg project linking Swiss and French research groups. Mission is to develop an in vitro platform to screen nanotherapies against lung cancer.

epithelix.com
8OncoTheis
Strategic tierCoreTypeStrategic or Co-development Partner
Description

OncoTheis is a biotech company dedicated to developing innovative bioengineered tissues and organoids for cancer research. Produces integrated 3D in vitro models combining healthy and compromised tissues.

epithelix.com
Strategic tierCoreTypeTechnology or Integration
Description

VirNext is a spin-off of Université Claude Bernard Lyon 1 created within the VirPath laboratory. Epithelix partners with VirNext to provide in vitro testing for SARS-CoV-2 infection using BSL-3 facility.

10Iwaki & Co., LTD
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Japanese distributor for Epithelix products. Distribution agreement signed January 2010. Located in Tokyo, Japan.

epithelix.com
11Institute of In Vitro Sciences (IIVS)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

US distributor for Epithelix products. Located in Gaithersburg, MD, USA.

epithelix.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

South Korean distributor for Epithelix products. Located in Seoul, South Korea.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Indian distributor for Epithelix products. Located in Mumbai, India.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MatTek produces reconstructed human 3D tissue models (EpiDerm, EpiOcular, EpiAirway) using primary epithelial cells cultured at air-liquid interface, directly overlapping Epithelix's MucilAir airway tissue products and serving similar cosmetic, chemical, and pharmaceutical safety testing customers.

TypeDirect peer
Description

Emulate develops organ-on-chip platforms with multiple tissue types including airway and lung chips, directly competing for the same in vitro respiratory drug development and toxicology budgets that Epithelix addresses.

3CN Bio
TypeDirect peer
Description

CN Bio offers organ-on-chip and MPS systems including lung models for drug development and toxicology, competing with Epithelix in respiratory in vitro testing for pharma and consumer products customers.

TypeEmerging player
Description

Mimetas develops OrganoPlate organ-on-chip technology covering multiple tissues including airway models, representing an emerging alternative to Epithelix's 3D reconstituted tissue approach for respiratory research.

TypeEmerging player
Description

TissUse builds multi-organ-chip (MOC) and HUMIMIC systems for substance testing and disease modeling, including respiratory applications, providing an integrated platform that overlaps with Epithelix's MPS positioning.

TypeEmerging player
Description

InSphero produces 3D microtissue and organoid models for drug discovery and toxicology, with similar in vitro alternative testing focus and pharma/CRO customer base as Epithelix, though broader across organ types.

TypeEmerging player
Description

CellnTec supplies primary epithelial cells and 3D air-liquid interface culture technologies, overlapping with Epithelix's hAEC/hSAEC cell product lines and airway tissue culture workflows.

TypeBroad incumbent
Description

Lonza is a major contract manufacturer of cell and gene therapies and primary cells used in respiratory research; its scale and broad portfolio in biologics manufacturing position it as a broad incumbent competitor to specialty tissue providers like Epithelix.

TypeBroad incumbent
Description

PMI's reduced-risk product R&D relies on in vitro human airway models for aerosol and inhalation toxicology assessment, making it both a sophisticated buyer and a potential internal competitor to commercial tissue suppliers like Epithelix.

TypeOthers
Description

Vitrocell manufactures exposure systems for in vitro inhalation toxicology (Cloud, VC1) that are adapted for use with Epithelix's tissues; while not a direct tissue competitor, it is a close technology partner and ecosystem enabler in the same customer workflow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Epithelix

In Vitro Respiratory Tissue Modelsepithelix.com

Epithelix Sàrl develops and commercializes proprietary in vitro 3D reconstituted human respiratory epithelium tissues (MucilAir™, SmallAir™, AlveolAir™) and related contract research services, serving pharmaceutical, chemical, cosmetics, medical-device, academic and government customers seeking alternatives to animal respiratory testing.

What Epithelix does

Epithelix Sàrl, founded in March 2006 in Plan-les-Ouates (Geneva, Switzerland) by three University of Geneva scientists — Dr. Samuel Constant, Dr. Song Huang and Dr. Ludovic Wiszniewski — develops and commercializes in vitro 3D reconstituted human respiratory epithelium tissues cultured at the air-liquid interface (ALI) as alternatives to animal experimentation. The company's core platform consists of three primary tissue models: MucilAir™ (upper respiratory tract, available in nasal, tracheal and bronchial variants), SmallAir™ (lower respiratory tract / bronchiolar region) and AlveolAir™ (alveolar epithelium), each maintained in a proprietary differentiated and functional state for more than one year — a performance capability the company positions as unique versus other respiratory models. The product range is broadened by advanced co-culture versions (with primary human fibroblasts or alveolar macrophages), pathological-tissue variants (Smoker, Allergic Rhinitis, Asthma, COPD, Cystic Fibrosis), cryopreserved primary cells (hAEC, hSAEC, fibroblasts, pneumocytes, alveolar macrophages) and a suite of serum-free, chemically defined culture media.

Revenue is generated through two complementary streams: (1) catalog product sales of tissues, cryopreserved cells, media and companion reagents on a one-time-purchase basis, and (2) contract research (CRO) services covering viral and bacterial infection assays, nasal spray evaluation, inhalation toxicity, anti-inflammatory and cystic fibrosis efficacy testing, absorption/permeation, metaplasia, mucolytic activity, nasal dryness, wound healing, electrophysiology, and mucociliary clearance analysis, supported by exposure systems (Vitrocell Cloud, Vitrocell VC1, NanoPress) and the proprietary Cilia-X CBF analysis software. Pricing is quote-based via direct email requests, with free test samples offered to new accounts. The go-to-market combines direct sales from Swiss and French facilities with regional channel partners in the US (Institute of In Vitro Sciences), Japan (Iwaki & Co., since January 2010), South Korea (BN Korea) and India (Krishgen BioSystems); customer segments span pharmaceutical, chemical/consumer products (including cosmetics and inhalation product testing), academic research, government/regulatory bodies, and medical-device developers, with named users including Johns Hopkins School of Medicine, Public Health England, the Slovak Academy of Sciences and the University of Freiburg. The company is self-financed (no disclosed external equity), maintains a wholly-owned French subsidiary and a wholly-owned cancer-research spin-off (OncoTheis), and reports a headcount of 20+ full-time staff across both sites.

Epithelix firmographics

Firmographics
Name
Epithelix
Legal name
Epithelix Sàrl
Website
https://epithelix.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Epithelix Sàrl develops and commercializes proprietary in vitro 3D reconstituted human respiratory epithelium tissues (MucilAir™, SmallAir™, AlveolAir™) and related contract research services, serving pharmaceutical, chemical, cosmetics, medical-device, academic and government customers seeking alternatives to animal respiratory testing.
Ownership category
akta.pro rank

Epithelix industry classification

Industry
Product category
In Vitro Respiratory Tissue Models
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKANAD
Asthma & Allergy-Related Pulmonary Care

Keywords

  • In vitro respiratory tissues
  • 3D airway epithelium models
  • Preclinical inhalation toxicology
  • Alternatives to animal testing
  • Human respiratory tissue models

Where Epithelix is headquartered

Location

Headquarters

HQ city
Plan-les-ouates
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Epithelix business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Tissue and Cell Products: Sale of in vitro reconstituted human respiratory tissues (MucilAir, SmallAir, AlveolAir) and cryopreserved primary cells (hAEC, hSAEC, fibroblasts, alveolar pneumocytes, alveolar macrophages) along with specialized culture media.
  2. Contract Research Services (CRO): In vitro testing services including viral infections, bacterial infections, nasal spray evaluation, inhalation toxicity, anti-inflammatory, cystic fibrosis, absorption-permeation, metaplasia, mucolytic activity, nasal dryness, wound healing assays, electrophysiology, and mucociliary clearance analysis.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Epithelix product offering

Product offering

Core offering

Epithelix develops and sells in vitro 3D reconstituted human respiratory epithelium tissues (MucilAir™, SmallAir™, AlveolAir™) cultured at air-liquid interface, along with co-culture models, cryopreserved primary airway cells, tissue-specific serum-free culture media, the proprietary Cilia-X analysis software, and a suite of contract research testing services for respiratory drug development, inhalation toxicology, infectious disease research, and disease modeling.

Product overview

Epithelix provides a comprehensive portfolio of in vitro respiratory solutions centered on reconstituted human 3D airway tissues and associated testing services. The core product line includes three primary 3D tissue models: MucilAir™ (upper respiratory epithelium available in nasal, tracheal, and bronchial versions), SmallAir™ (lower bronchiolar epithelium), and AlveolAir™ (alveolar epithelium). These are complemented by advanced co-culture models incorporating fibroblasts or macrophages, and an extensive catalog of cryopreserved primary cells (hAEC, hSAEC, pneumocytes, alveolar macrophages, fibroblasts). Supporting the tissue products are purpose-designed serum-free culture media for each tissue type. As a CRO, Epithelix offers extensive testing services including viral/bacterial infection assays, inhalation toxicity, drug absorption studies, anti-inflammatory evaluation, and specialized endpoints such as electrophysiology and mucociliary clearance analysis. The company also provides proprietary analysis software (Cilia-X) and exposure devices for aerosol testing.

Differentiator

Problem solved

Functional benefit

Brands

  • MucilAir™: In vitro 3D human respiratory epithelium model from nasal, tracheal, or bronchial origin. The only human respiratory epithelium model able to remain fully differentiated and functional for more than one year.
  • SmallAir™
  • AlveolAir™
  • MucilAir™ Pool
  • SmallAir™ Pool
  • Cilia-X
  • LIVe

Products and services

  • MucilAir™ In vitro 3D reconstituted human upper respiratory epithelium comprising basal, goblet, and ciliated cells, available in nasal, tracheal, and bronchial regions, for pharmaceutical, chemical, cosmetics, and academic respiratory research.
  • SmallAir™ In vitro 3D reconstituted human bronchiolar epithelium model targeting the small airways for research on asthma, COPD, and bronchiolar disease.
  • AlveolAir™ In vitro 3D reconstituted human alveolar epithelium model for studying deep-lung biology, drug delivery, and alveolar pathology.
  • MA / SA -HF Advanced Co-culture Models MucilAir or SmallAir tissue co-cultured with primary human pulmonary fibroblasts for studies requiring stromal-epithelial interactions.
  • MA / SA / AA -Macrophages Co-culture Models Epithelial tissues combined with primary human alveolar macrophages for modelling innate immune and inflammatory responses in the respiratory tract.
  • hAEC Upper Airway Epithelial Cells Cryopreserved low-passage primary human upper airway epithelial cells supplied for 2D or ALI culture use in respiratory research.
  • hSAEC Small Airway Epithelial Cells Cryopreserved low-passage primary human small airway epithelial cells for use in disease modeling and toxicology research.
  • Pulmonary Fibroblasts (HF) Cryopreserved low-passage primary human pulmonary fibroblasts for co-culture and stromal interaction studies.
  • Alveolar Pneumocytes Cryopreserved low-passage primary human alveolar pneumocytes (Type I and Type II) for alveolar biology and inhalation studies.
  • Alveolar Macrophages Cryopreserved primary human resident alveolar macrophages (more than 1 million viable cells per vial) for co-culture, innate immunity, and infection studies.
  • Cells and Tissues Extracts Prepared extracts (mucus, total RNA, protein lysate) from MucilAir tissues for downstream biochemical and omics analyses.
  • Tissue-specific Serum-free Culture Media (MucilAir / SmallAir / AlveolAir / hAEC-hSAEC / Macrophage / Pneumocyte) Serum-free chemically defined culture media tailored to each Epithelix tissue and primary cell type, available in formats such as 125 mL and 500 mL bottles.
  • Cilia-X CBF Analysis Software Proprietary cross-platform web application for batch cilia beating frequency analysis, supporting image series, video files, and Nikon ND2 files with automated reporting.
  • In Vitro Contract Research Testing Services (CRO) Fee-for-service in vitro testing on Epithelix airway tissues including viral and bacterial infection assays, inhalation toxicity, anti-inflammatory studies, cystic fibrosis assays, absorption/permeation, metaplasia, mucolytic activity, nasal dryness, wound healing, electrophysiology, mucociliary clearance, and endpoint measurements for pharmaceutical, chemical, cosmetics, and academic clients.
  • Inhalation Exposure Devices Static and dynamic exposure devices including NanoPress (solid tablets), Vitrocell Cloud (nebulized liquids), and Vitrocell VC1 (gas or smoke) for testing airborne substances on Epithelix tissues, supplied and integrated for client studies.

Quantifiable outcome

  • Tissues can remain fully differentiated and functional for more than one year
  • +3 more outcomes

Companies that use Epithelix

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Epithelix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

Feature9 records

Epithelix partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core, major, minor and regional.

  • Vitrocell SystemscoreTechnology or IntegrationVitrocell Systems offers culture and exposure systems for in vitro studies on gases or complex mixtures. The VITROCELL modules adapted to MucilAir and SmallAir provide new possibilities for characterizing effects of airborne substances such as gas, nanoparticles, and complex mixtures.
  • PanviprepmajorStrategic or Co-development PartnerThe PANVIPREP consortium incorporates 14 European partners working to contribute to antiviral pandemic preparedness by piloting and progressing antiviral drug development targeting RNA virus families with high epidemic or pandemic potential.
  • NosevacmajorStrategic or Co-development PartnerNOSEVAC consortium aims to cultivate and evaluate inventive nasal vaccine platforms to prevent earliest stage of infection and inhibit upper respiratory tract colonisation and transmission. Funding from EU, UK, and Swiss governments.
  • MACRAMÉmajorStrategic or Co-development PartnerMACRAMÉ Project aligned with EU ambitions for safety and sustainability of chemicals, focusing on nanomaterials and Advanced Materials. Development of novel methodologies for inhalable carbon-based materials including graphene-related materials and carbon nanotubes.
  • FAIRcoreStrategic or Co-development PartnerFAIR is an EU Horizon 2020 project that aims at evaluating the activation of the innate immune system in the airways. Provides an alternative adjunct strategy to standard of care antibiotics for treating pneumonia caused by antibiotic-resistant bacteria.
  • OrganovircoreStrategic or Co-development PartnerOrganoVIR is a Horizon 2020 Marie Sklowdowska-Curie Actions Innovative Training Network (MSCA-ITN) that trains 15 Early Stage Researchers to lead innovation in organoids for virology. Epithelix is a partner in the consortium.
  • OnconanoscreenminorStrategic or Co-development PartnerOnconanoscreen is an Interreg project linking Swiss and French research groups. Mission is to develop an in vitro platform to screen nanotherapies against lung cancer.
  • OncoTheiscoreStrategic or Co-development PartnerOncoTheis is a biotech company dedicated to developing innovative bioengineered tissues and organoids for cancer research. Produces integrated 3D in vitro models combining healthy and compromised tissues.
  • VirnextcoreTechnology or IntegrationVirNext is a spin-off of Université Claude Bernard Lyon 1 created within the VirPath laboratory. Epithelix partners with VirNext to provide in vitro testing for SARS-CoV-2 infection using BSL-3 facility.
  • Iwaki & Co., LTDcoreChannel Partner/ Reseller/ DistributorJapanese distributor for Epithelix products. Distribution agreement signed January 2010. Located in Tokyo, Japan.
  • Institute of In Vitro Sciences (IIVS)coreChannel Partner/ Reseller/ DistributorUS distributor for Epithelix products. Located in Gaithersburg, MD, USA.
  • BN KorearegionalChannel Partner/ Reseller/ DistributorSouth Korean distributor for Epithelix products. Located in Seoul, South Korea.
  • Krishgen BioSystemsregionalChannel Partner/ Reseller/ DistributorIndian distributor for Epithelix products. Located in Mumbai, India.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Epithelix competitors and assessment

Company assessment

Direct peers

  • MatTek Life Sciences: MatTek produces reconstructed human 3D tissue models (EpiDerm, EpiOcular, EpiAirway) using primary epithelial cells cultured at air-liquid interface, directly overlapping Epithelix's MucilAir airway tissue products and serving similar cosmetic, chemical, and pharmaceutical safety testing customers.
  • Emulate Inc. Emulate develops organ-on-chip platforms with multiple tissue types including airway and lung chips, directly competing for the same in vitro respiratory drug development and toxicology budgets that Epithelix addresses.
  • CN Bio: CN Bio offers organ-on-chip and MPS systems including lung models for drug development and toxicology, competing with Epithelix in respiratory in vitro testing for pharma and consumer products customers.

Emerging players

  • Mimetas: Mimetas develops OrganoPlate organ-on-chip technology covering multiple tissues including airway models, representing an emerging alternative to Epithelix's 3D reconstituted tissue approach for respiratory research.
  • TissUse: TissUse builds multi-organ-chip (MOC) and HUMIMIC systems for substance testing and disease modeling, including respiratory applications, providing an integrated platform that overlaps with Epithelix's MPS positioning.
  • InSphero: InSphero produces 3D microtissue and organoid models for drug discovery and toxicology, with similar in vitro alternative testing focus and pharma/CRO customer base as Epithelix, though broader across organ types.
  • CellnTec: CellnTec supplies primary epithelial cells and 3D air-liquid interface culture technologies, overlapping with Epithelix's hAEC/hSAEC cell product lines and airway tissue culture workflows.

Broad incumbents

  • Lonza Group: Lonza is a major contract manufacturer of cell and gene therapies and primary cells used in respiratory research; its scale and broad portfolio in biologics manufacturing position it as a broad incumbent competitor to specialty tissue providers like Epithelix.
  • Philip Morris International (in vitro biology R&D): PMI's reduced-risk product R&D relies on in vitro human airway models for aerosol and inhalation toxicology assessment, making it both a sophisticated buyer and a potential internal competitor to commercial tissue suppliers like Epithelix.

Others

  • Vitrocell Systems: Vitrocell manufactures exposure systems for in vitro inhalation toxicology (Cloud, VC1) that are adapted for use with Epithelix's tissues; while not a direct tissue competitor, it is a close technology partner and ecosystem enabler in the same customer workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Epithelix social profiles

Digital presence

Epithelix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Epithelix leadership team

Management profile

Number of profiles

Profiles3 records

Epithelix subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Epithelix funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Epithelix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epithelix

What does Epithelix do?

Epithelix develops and sells in vitro 3D reconstituted human respiratory epithelium tissues (MucilAir™, SmallAir™, AlveolAir™) cultured at air-liquid interface, along with co-culture models, cryopreserved primary airway cells, tissue-specific serum-free culture media, the proprietary Cilia-X analysis software, and a suite of contract research testing services for respiratory drug development, inhalation toxicology, infectious disease research, and disease modeling.

Is Epithelix a public or private company?

Epithelix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Epithelix founded?

Epithelix was founded in 2006. It employs 11 to 50 people.

Where is Epithelix based?

Epithelix is headquartered in Plan-les-ouates, Switzerland, in the Europe region.

How does Epithelix make money?

Two revenue lines are on record. Tissue and Cell Products are the primary driver. The others are contract Research Services (CRO).

Who are Epithelix's main competitors?

Direct peers on record are MatTek Life Sciences, Emulate Inc. and CN Bio. Emerging players are Mimetas, TissUse, InSphero and CellnTec. Broad incumbents are Lonza Group and Philip Morris International (in vitro biology R&D). Vitrocell Systems is listed as an others.

Does Epithelix have an API?

No public API is recorded for Epithelix.

What industry is Epithelix in?

Epithelix's product category is In Vitro Respiratory Tissue Models. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals